Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Gonorrhea: Prevention and Risk Reduction: Barrier Protection, Multi-Site Screening, Partner Treatment Protocols, and Antimicrobial Stewardship

A sexual health reference on barrier protection including oral sex, site-specific screening schedules, partner notification and expedited partner therapy, test of cure and retesting, and doxy-PEP and vaccine developments.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This is an accurate and current brief, and it covers the two things most prevention writing misses: site-specific testing, and the fact that pharyngeal infection is a major silent reservoir. The doxy-PEP and 4CMenB sections are correctly hedged. The notes below are additions and one treatment update.
  • The treatment described in passing is out of date in one respect, and it matters because it appears throughout older material. Azithromycin is no longer routinely co-administered with ceftriaxone for gonorrhea. Current guidance is ceftriaxone alone, by intramuscular injection, with doxycycline added only when chlamydia has not been excluded. The brief's reference to single-dose intramuscular ceftriaxone is correct; the omission of this change leaves readers to fill the gap from older sources.
  • The doxy-PEP section is well judged and needs its target population. It is recommended for specific groups, principally men who have sex with men and transgender women with a recent bacterial STI, rather than as general advice. Trials in cisgender women have not shown the same benefit. The resistance concern the brief raises is the live question, and it applies to gonorrhea more than to the other two targets.
  • Expedited partner therapy has a limitation specific to gonorrhea that should be stated. First-line treatment is an injection, so what can be given to an unseen partner is an oral alternative that is less effective, particularly for pharyngeal infection. EPT reduces reinfection and remains second best to a partner being seen and treated properly.
  • Screening of men who have sex only with women is not addressed. Routine screening is not currently recommended for that group in most guidelines, which is a recognized gap rather than an oversight, and a reader will otherwise assume their absence from the list means they are not at risk.
  • The window period is missing. A test taken immediately after a possible exposure can be negative while an infection is establishing, so a repeat test about two weeks later is often advised. Without this, the pre-intimacy testing advice can give false reassurance.
  • Disseminated gonococcal infection is mentioned once in the opening and never explained. The warning signs are worth naming: joint pain and swelling, fever, and a rash of small spots, appearing after a genital or pharyngeal infection. It is uncommon and needs hospital treatment.
  • Two additions to the neonatal section. The routine eye ointment given at birth is erythromycin, which prevents gonococcal eye infection and does not prevent chlamydial conjunctivitis. And gonococcal eye infection in an adult is also an emergency, because it can damage sight within days.
  • Gonorrhea increases the risk of acquiring and transmitting HIV, which is a reason the brief's screening recommendations and PrEP are linked. Stating that connection would strengthen the case for the screening intervals it recommends.
  • Everything else in the brief is accurate: the anatomical sites infected and the frequency of asymptomatic pharyngeal, rectal and cervical infection; the complications of untreated infection including PID, infertility, chronic pelvic pain and ectopic pregnancy; condom and dam use including for oral sex and shared toys; the screening recommendations for women under 25 and for MSM, people on PrEP and people living with HIV at three to six month intervals; the finding that urine-only testing misses the large majority of extragenital infections; prenatal screening and neonatal prophylaxis; seven days of abstinence after treatment for both partners; partner notification covering the previous 60 days; test of cure at 7 to 14 days for pharyngeal infection; retesting at three months for everyone; and the reported efficacy ranges for doxy-PEP and for 4CMenB cross-protection.

Download the PDF

All source documents